Essentials for Scientists in Academia and Industry

Historically, drug discovery is a lengthy, expensive, difficult, and inefficient process. But there is light at the end of the tunnel. We are inviting experts from academia and industry in order to elucidate the drug discovery process from basic research and target identification, including further characterization and development. For every step we provide state-of-the-art technology that can significantly improve your results.

Agilent Seahorse XF Technology – Measure what’s important to your cells

Using Agilent Seahorse XF Analyzers, scientists are continuing to obtain powerful functional data from live cells, in real time, gaining a greater understanding of cell metabolism. With this event we aim to provide an overview of the broad range of applications and to highlight the huge impact functional metabolism has.

This webinar, the second of the “Women in Single Cell” series, will discuss the use of single-cell technologies to investigate clonal architecture and genotype/immunophenotype relationships in myeloid malignancies.

Abstract:
Acute myeloid leukemia (AML) derives from genetic and epigenetic events that lead to abnormal clonal expansion and evolution of hematopoietic stem/progenitor cells (HSPCs). Bulk genomic sequencing studies in AML patients suggest that stepwise acquisition of somatic mutations is critical in driving AML development, progression, and maintenance. However, bulk sequencing is unable to delineate co-occurring mutations at a clonal level or clearly elucidate mutation order.

Dr. Linde A. Miles will discuss her recent publication in Nature in which she and colleagues performed single-cell DNA sequencing on samples from patients with myeloid malignancies, including AML patients. They used a custom panel spanning the 31 most frequently mutated AML genes with the Mission Bio Tapestri single-cell sequencing platform. The team identified gene-specific patterns within the dominant clones and uncovered synergistic co-mutations in AML capable of promoting clonal dominance and expansion. They also combined single-cell mutational analysis with cell surface protein expression to map clonal architecture and genotype/immunophenotype relationships.

Dr. Miles will also discuss newer studies using single-cell multi-omics that focus on the correlations between co-occurring mutations and immunophenotype. Findings from these studies provide a better understanding of clonal evolution in leukemic transformation and progression.

Speaker:
Linde A. Miles, PhD
Memorial Sloan Kettering Cancer Center

Plenary speakers of the meeting will be:

• Prof. Ralf Brandes (Vascular Research Centre. Frankfurt am Mainz, DE)
• Prof. Miriam Stoeber (University of Geneva, CH)

Another highlight is the awarding of the Young Investigator Award by the "Stiftung Physiology" (former Oetliker Foundation) to the best posters & best talks!

The conference is planned as an on-site meeting, with all necessary measures to ensure a safe meeting.

ILMAC is Switzerland’s leading trade fair for experts from more than 20 different branches of industry. Roughly half the visitors to ILMAC come from the pharmaceutical and chemical industries. In addition, mechanical, plant and apparatus engineering professionals, and also laboratory and biotechnology experts similarly use ILMAC as a contact platform.

Stop by at our Booth B163